End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
42.9 CNY | +5.07% | +1.66% | -20.11% |
03-28 | Beijing Tongrentang Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-06 | China Approves Tong Ren Tang Group's Clinical Trial of Heart Failure Drug | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With an expected P/E ratio at 30.3 and 26.29 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.11% | 8.12B | C- | ||
+25.83% | 661B | C+ | ||
+27.00% | 566B | B | ||
-6.76% | 352B | C+ | ||
+20.34% | 332B | B- | ||
+3.00% | 283B | C+ | ||
+13.09% | 231B | B+ | ||
+5.46% | 200B | B- | ||
-9.61% | 195B | A+ | ||
-6.26% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600085 Stock
- Ratings Beijing Tongrentang Co., Ltd